System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Joan Palou is an expert in Urology at Autonomous University of Barcelona (Spain). As of October 2026, ScienceLeadR ranks Joan Palou in the top 1% of experts worldwide for Urinary Bladder Diseases and Urologic Neoplasms. Joan Palou has authored 853 publications, the most recent in 2027, and is an investigator in 10 clinical trials, 3 of them ongoing. SLR score: 2,534 (community average: 125). How the SLR is computed.

LeadR Profile

Joan Palou Autonomous University of Barcelona Spain
2 534 ScienceLeadR Reputation 2534

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology - Surgery - Nephrology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2027
Source: PubMed

Puigvert Foundation

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 853

Citations

Citations: 23 604 1st author: 59 Last author: 108 Unique author: 4

Main journals

J Urol 126
Eur Urol 108
EUR UROL SUPPL 89
Actas Urol Esp 58
Eur Urol Open Sci 50

Best Journals

J Clin Oncol 5
Ann Oncol 2
Nat Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Neoadjuvant Therapy in Patients with Upper Tract Urothelial Cancer: An Updated Systematic Review and Meta-analysis.
PMID 42934012 — neoplasms, neoadjuvant therapy, therapeutics		Eur Urol Oncol20260
Response: Misclassification of Evidence Regarding Prolonged Antibiotic Prophylaxis in the Latin American Consensus on Robot-Assisted Radical Cystectomy.
PMID 42776561 — antibiotic prophylaxis, cystectomy		Int Braz J Urol20270
Durvalumab in Combination with Bacillus Calmette-Guérin Induction and Maintenance Therapy for Bacillus Calmette-Guérin-Naïve, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.
PMID 42713893 — urinary bladder, urinary bladder neoplasms, urology, safety, muscles, neoplasms, bacillus, maintenance, therapeutics, non-muscle invasive bladder neoplasms		J Urol20260
Robot-assisted versus open kidney transplantation in patients who previously underwent an open kidney transplant.
PMID 42696009 — urology, safety, kidney, kidney failure, chronic, transplants, kidney transplantation, transplantation, postoperative complications		World J Urol20260
Corrigendum to "Robot-assisted renal auto transplantation: state of the art" [Eur Urol Focus 2026; Volume: Online ahead of print. doi: 10.1016/j.euf.2026.06.029].
PMID 42697766 — urology, urologic diseases, transplantation		Eur Urol Focus20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 5
Phase 3 2
Phase 1 1
Phase 2 1
Phase 4 1

By status:

Active not recruiting 5
Completed 2
Recruiting 2
Not yet recruiting 1

By type:

Interventional 6
Observational 4

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non muscle invasive bladder cancer versus the standard immunotherapy
2024-520006-19-00 — urinary bladder, urinary bladder neoplasms, mitomycin, safety, muscles, pharmaceutical preparations, neoplasms, maintenance, immunotherapy, therapeutics, therapeutic uses, non-muscle invasive bladder neoplasms, medical devices		Phase 4Not yet recruiting2021
European Registry of Next Generation Imaging in Advanced Prostate Cancer
NCT06866782 — registries, choline, neoplasms, prostate, magnetic resonance imaging, positron emission tomography computed tomography, biomarkers, prostatic neoplasms, therapeutics, membranes, men, bone and bones		N/ARecruiting2024
External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
NCT05864599 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, biomarkers, non-muscle invasive bladder neoplasms		N/AActive not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS